跳轉至內容
Merck
全部照片(2)

重要文件

檢視所有文件

G9518

Sigma-Aldrich

吉非罗齐

同義詞:

2,2-二甲基-5-(2,5-二甲基苯氧基)戊酸, 2,2-二甲基-5-(2,5-二甲苯氧基)戊酸, 5-(2,5-二甲基苯氧基)-2,2-二甲基戊酸

登入查看組織和合約定價
全部照片(2)

About This Item

經驗公式（希爾表示法）:
C15H22O3
CAS號碼:
25812-30-0
分子量：:
250.33
EC號碼:
247-280-2
MDL號碼:
MFCD00079335
分類程式碼代碼:
12352200
PubChem物質ID:
24895377
NACRES:
NA.77

形狀

powder

品質等級

100

SMILES 字串

Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1

InChI

1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)

InChI 密鑰

HEMJJKBWTPKOJG-UHFFFAOYSA-N

基因資訊

human ... PPARA(5465)

尋找類似的產品？ 前往 產品比較指南

一般說明

吉非罗齐是一种纤维酸衍生物和降血脂药。吉非罗齐可作为 PPARα（过氧化物酶体增殖物激活受体 α）的配体。

應用

吉非罗齐已被用于研究其对酵母细胞周期进程的影响。它已被用于研究贝特类药物对人细胞系中细胞增殖和基因表达的影响。

生化／生理作用

吉非罗齐选择性增加载脂蛋白 A-I 水平。在酵母细胞中，吉非罗齐的应用会延迟 DNA 复制的开始。它被用作血脂异常的治疗药物。

特點和優勢

这种化合物是ADME毒性研究的特色产品。点击此处发现更多特色ADME毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

象形圖

Exclamation mark
GHS07

訊號詞

Warning

危險聲明

H302

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves

從最近期的版本中選擇一個：

分析證明 (COA)

Lot/Batch Number
BCCG9003
BCBP4924
BCBP4924V
030M1424V
SLBD3802V

未看到正確版本？

如果您需要一個特定的版本，您可以透過批號來尋找特定憑證。

搜尋 COA

已經擁有該產品？

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Katerina Cizkova et al.
Lipids in health and disease, 15(1), 164-164 (2016-09-24)
Fibrates are widely used hypolipidemic drugs, which serve as ligand of peroxisome proliferator-activated receptor α (PPARα). Recently, they have also been considered as potential anticancer agents. We studied effect of fibrates treatment on cell proliferation, expression of CYP2J2 and concomitant
Gianluca Miglio et al.
British journal of pharmacology, 167(3), 641-653 (2012-05-19)
Peroxisome proliferator-activated receptor (PPAR) agonists exert anti-albuminuric effects. However, the nephroprotective effects of these drugs remain to be fully understood. We have investigated whether gemfibrozil, GW0742 and pioglitazone protect human podocytes against nutrient deprivation (ND)-induced cell death and the role
Amir Qaseem et al.
Annals of internal medicine, 159(12), 835-847 (2013-10-23)
The American College of Physicians (ACP) developed this guideline to present the evidence and provide clinical recommendations on the screening, monitoring, and treatment of adults with stage 1 to 3 chronic kidney disease. This guideline is based on a systematic
Scott A Hoose et al.
PloS one, 7(5), e36503-e36503 (2012-05-09)
Screening chemical libraries to identify compounds that affect overall cell proliferation is common. However, in most cases, it is not known whether the compounds tested alter the timing of particular cell cycle transitions. Here, we evaluated an FDA-approved drug library
Ana Maria Sierra Villar et al.
International journal of pharmaceutics, 431(1-2), 161-175 (2012-04-14)
Self-nanoemulsifying drug delivery systems of gemfibrozil were developed under Quality by Design approach for improvement of dissolution and oral absorption. Preliminary screening was performed to select proper components combination. Box-Behnken experimental design was employed as statistical tool to optimize the
查看所有相關論文

文章

Cholesterol Transport

Since cholesterol is a water-insoluble molecule it must be packaged for transport within the plasma. The particles that package cholesterol, cholesteryl esters, and triglycerides for transport, are called lipoproteins.

Cholesterol Transport

Since cholesterol is a water-insoluble molecule it must be packaged for transport within the plasma. The particles that package cholesterol, cholesteryl esters, and triglycerides for transport, are called lipoproteins.

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

Antilipemic Agents

Randomized controlled clinical studies have suggested 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are effective in both primary and secondary prevention of cardiovascular disease (CVD) events.

我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務